Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet expectations for use as a standalone therapy. Hardman Johnston Global Equity Strategy has exited its position in the company following these developments. The company has decided not to pursue VX-993 as a monotherapy, which signals a shift in how its non cystic fibrosis assets are being viewed. Vertex is best known for its cystic fibrosis franchise, but it has been working to build out a broader portfolio that includes non opioid pain therapies. The recent FDA feedback on Journavx and the phase II readout for VX-993 put fresh attention on how much weight investors place on this part of the pipeline. With a large equity fund stepping away, many investors are rechecking how they think about risk across Vertex's different therapeutic areas. For you as an investor, the key question is how m
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]Yahoo! Finance
- Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]Yahoo! Finance
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/3/25 - Beat
VRTX
Sec Filings
- 2/3/26 - Form 3
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- VRTX's page on the SEC website